Financial Statements

Bristol-Myers Squibb Company (BMY)


-0.24 (-0.36%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) 23,82021,28134,47434,065-
Net Income 6,3276,994-9,0153,4394,920
Stock Dividends -10-59-103-35131,758
Dividend Paid -4,634-4,396-4,075-2,679-2,613
Retained Earnings 25,50323,82021,28134,47434,065

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 6,9686,7456,2525,027-
Annual Depreciation 4051,1961,2462,0615,978
Capital Expenditure -1,118-973-753-836-951
Net PPE 6,2556,9686,7456,2525,027

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -6,53822,48820,54720,502
New Purchases -2,305-3,961-4,172-5,478-3,592
Intangible and Goodwill 6,53822,48820,54720,50221,149

Bristol-Myers Squibb Company income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Bristol-Myers Squibb Company FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.